Virchows Archiv

, Volume 475, Issue 4, pp 415–424 | Cite as

Molecular and clinicopathological analyses of esophageal carcinosarcoma with special reference to morphological change

  • Sho Tsuyama
  • Tsuyoshi SaitoEmail author
  • Yoichi Akazawa
  • Yuka Yanai
  • Noboru Yatagai
  • Keisuke Akaike
  • Takuo Hayashi
  • Yoshiyuki Suehara
  • Fumiyuki Takahashi
  • Kazuya Takamochi
  • Takashi Hashimoto
  • Yoshiaki Kajiyama
  • Masahiko Tsurumaru
  • Tetsu Fukunaga
  • Takashi Yao
Original Article
Part of the following topical collections:
  1. Quality in Pathology


The molecular pathogenesis of esophageal carcinosarcoma (ECS) has not been fully investigated. This study includes 16 consequent cases of surgically resected ECS. Genetic alterations were independently examined for carcinoma in situ, carcinomatous, and sarcomatous areas. Six cases were analyzed by next-generation sequencing, and the remaining cases were analyzed by Sanger sequencing for TP53, PTEN, and INI1. Sarcomatous components in 3 cases showed histologically heterogenous feature of osteosarcoma. Lymph node metastasis was found in 12 out of 16 cases. Survival analysis revealed 5-year overall survival rate of 59.9%, and the median survival time was 5.37 years. TP53 was the most frequently mutated gene, being identified in 11 of 16 patients (68.8%), 7 of whom (63.6%) had the same mutations in both carcinomatous and sarcomatous areas. Almost complete concordance was found between p53 immunohistochemistry and TP53 missense mutations. Five-year overall survival tended to be worse for patients with p53 overexpression, although the data was not significant (p = 0.186). Nine of 16 patients (56.3%) showed loss of heterozygosity (LOH) at the INI1 locus, and this LOH status was consistent with both components. However, interestingly, INI1 expression was preserved in all cases. In addition, copy number variation analysis revealed gene amplification in several tyrosine kinase receptors. Accumulation of mutations in tumor suppressor genes such as TP53 and INI1 seemed to occur during ECS development.


Esophageal carcinosarcoma Next-generation sequencing TP53 INI1 LOH Tumorigenesis 





Loss of heterozygosity



We thank Noriko Sasahara, Isao Kurahayashi, Tomomi Saito, Hiroshi Sonoue, and Keiko Mitani for their excellent technical assistance. We thank the Laboratory of Molecular and Biochemical Research, Research Support Center, Juntendo University Graduate School of Medicine, for technical assistance.

Funding information

This study was financially supported in part by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports, and Culture (#17K08704 to Takashi Yao and #17K08730 to Tsuyoshi Saito), Tokyo, Japan. This research was supported by AMED under Grant Number JP17am0001009.

Compliance with ethical standards

This study was approved by the Ethical Committee of Juntendo University School of Medicine (2016108).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

428_2019_2643_Fig5_ESM.png (880 kb)
Supplementary Fig. 1:

Copy number variations. Several gains and losses were commonly observed both in carcinoma and sarcoma components, and several differences were also observed between these components. (PNG 880 kb)

428_2019_2643_MOESM1_ESM.tif (87 kb)
High resolution image (TIF 87 kb)
428_2019_2643_MOESM2_ESM.xlsx (12 kb)
Supplementary Table 1 (XLSX 11 kb)
428_2019_2643_MOESM3_ESM.xlsx (12 kb)
Supplementary Table 2 (XLSX 12 kb)
428_2019_2643_MOESM4_ESM.xlsx (11 kb)
Supplementary Table 3 (XLSX 11 kb)


  1. 1.
    Madan AK, Long AE, Weldon CB, Jaffe BM (2001) Esophageal carcinosarcoma. J Gastrointest Surg 5:414–417CrossRefGoogle Scholar
  2. 2.
    Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T (2017) Comprehensive Registry of Esophageal Cancer in Japan, 2010. Esophagus 14:189–214. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Japan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part I Esophagus 14:1–36. doi:
  4. 4.
    Bosman FT, Cameiro F, Hruban RH et al (2010) WHO classification of tumors of the digestive system, 4th edn. IARC, Lyon, p 20Google Scholar
  5. 5.
    Osamura RY, Shimamura K, Hata J, Tamaoki N, Watanabe K, Kubota M, Yamazaki S, Mitomi T (1978) Polypoid carcinoma of the esophagus. A unifying term for “carcinosarcoma” and “pseudosarcoma”. Am J Surg Pathol 2:201–208CrossRefGoogle Scholar
  6. 6.
    McCluggage WG (2002) Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55:321–325CrossRefGoogle Scholar
  7. 7.
    Matsumoto T, Fujii H, Arakawa A, Yamasaki S, Sonoue H, Hattori K, Kajiyama Y, Hirose S, Tsurumaru M (2004) Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma. Hum Pathol 35:322–327. CrossRefPubMedGoogle Scholar
  8. 8.
    Nakazawa T, Nobusawa S, Ikota H, Kuwano H, Takeyoshi I, Yokoo H (2015) Wide expression of ZEB1 in sarcomatous component of spindle cell carcinoma of the esophagus. Pathol Int 65:635–643. CrossRefPubMedGoogle Scholar
  9. 9.
    Iwaya T, Maesawa C, Tamura G, Sato N, Ikeda K, Sasaki A, Othuka K, Ishida K, Saito K, Satodate R (1997) Esophageal carcinosarcoma: a genetic analysis. Gastroenterology 113:973–977CrossRefGoogle Scholar
  10. 10.
    Brierley JD, Gospodarowicz MK, Wittekind C(eds).(2017) Union for International Cancer Control (UICC) TNM classification of malignant tumors 8th ed. Wiley-BlackwellGoogle Scholar
  11. 11.
    Akazawa Y, Saito T, Hayashi T, Yanai Y, Tsuyama S, Akaike K, Suehara Y, Takamochi K, Ueyama H, Murakami T, Watanabe S, Nagahara A, Yao T (2018) Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid Brierley JD, Gospodarowicz MK, Wittekind C (eds).(2017)Google Scholar
  12. 12.
    Yatagai N, Saito T, Akazawa Y, Hayashi T, Yanai Y, Tsuyama S, Ueyama H, Murakami T, Watanabe S, Nagahara A, Yao T (2019) TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation. Virchows Arch 474:315–324. CrossRefPubMedGoogle Scholar
  13. 13.
    Okubo T, Saito T, Mitomi H, Takagi T, Torigoe T, Suehara Y, Kaneko K, Yao T (2013) p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. Virchows Arch 463:67–77. CrossRefPubMedGoogle Scholar
  14. 14.
    Virchow R (ed) (1864) Die Krankhaften Geschwülste. A. Hirschwald, BerlinGoogle Scholar
  15. 15.
    Hansemann V (1904) Das gleichzeitige Vorkommen verschiedenartiger Geschwülste bei derselben. Person Krebsforschung 1:183–198Google Scholar
  16. 16.
    Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T (2018) Comprehensive Registry of Esophageal Cancer in Japan, 2011. Esophagus 15:127–152. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Iyomasa S, Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Itabashi M (1990) Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol 20:99–106PubMedGoogle Scholar
  18. 18.
    Sano A, Sakurai S, Kato H, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Sakamoto K, Sano T, Hosoya Y, Enomoto T, Kanda T, Ajioka Y, Oyama T, Kuwano H (2009) Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma. Anticancer Res 29:3375–3380PubMedGoogle Scholar
  19. 19.
    Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD (2008) Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 112:64–70. CrossRefPubMedGoogle Scholar
  20. 20.
    Bland AE, Stone R, Heuser C, Shu J, Jazaeri A, Shutter J, Atkins K, Rice L (2009) A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer 19:261–265. CrossRefPubMedGoogle Scholar
  21. 21.
    Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR (2006) Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol 103:684–687. CrossRefPubMedGoogle Scholar
  22. 22.
    Nicotina PA, Ferlazzo G, Vincelli AM (1997) Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors. Histol Histopathol 12:967–972PubMedGoogle Scholar
  23. 23.
    Sasajima K, Taniguchi Y, Morino K, Yamashita K, Onda M, Hao K, Takubo K (1988) Rapid growth of a pseudosarcoma of the esophagus. J Clin Gastroenterol 10:533–536CrossRefGoogle Scholar
  24. 24.
    Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305–318. CrossRefPubMedGoogle Scholar
  25. 25.
    Roberts CW, Biegel JA (2009) The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 8:412–416CrossRefGoogle Scholar
  26. 26.
    Kohashi K, Oda Y (2017) Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci 108:547–552. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Agaimy A, Hartmann A, Antonescu CR, Chiosea SI, El-Mofty SK, Geddert H, Iro H, Lewis JS Jr, Markl B, Mills SE, Riener MO, Robertson T, Sandison A, Semrau S, Simpson RH, Stelow E, Westra WH, Bishop JA (2017) SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 41:458–471. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kakkar A, Antony VM, Pramanik R, Sakthivel P, Singh CA, Jain D (2018) SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of thirteen cases with assessment of histological patterns. Hum Pathol. CrossRefGoogle Scholar
  29. 29.
    Hornick JL, Dal Cin P, Fletcher CD (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33:542–550. CrossRefGoogle Scholar
  30. 30.
    Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 137:581–588. CrossRefPubMedGoogle Scholar
  31. 31.
    Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck N. Engl J Med 357:2552–2561. CrossRefGoogle Scholar
  32. 32.
    Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157–1167. CrossRefPubMedGoogle Scholar
  33. 33.
    Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, De Paoli L, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 15:995–1004. CrossRefPubMedGoogle Scholar
  34. 34.
    Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y (2015) Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer 15:179. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bai Q, Zhang X, Zhu X, Wang L, Huang D, Cai X, Zhou X, Wang J, Sheng W (2016) Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour. Histopathology 69:393–405. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Sho Tsuyama
    • 1
  • Tsuyoshi Saito
    • 1
    • 2
    Email author
  • Yoichi Akazawa
    • 1
    • 3
  • Yuka Yanai
    • 1
  • Noboru Yatagai
    • 1
    • 3
  • Keisuke Akaike
    • 4
  • Takuo Hayashi
    • 1
  • Yoshiyuki Suehara
    • 2
    • 4
  • Fumiyuki Takahashi
    • 2
    • 5
  • Kazuya Takamochi
    • 6
  • Takashi Hashimoto
    • 7
  • Yoshiaki Kajiyama
    • 7
  • Masahiko Tsurumaru
    • 7
  • Tetsu Fukunaga
    • 8
  • Takashi Yao
    • 1
  1. 1.Department of Human PathologyJuntendo University School of MedicineTokyoJapan
  2. 2.Intractable Disease Research Center, Graduate School of MedicineJuntendo UniversityTokyoJapan
  3. 3.Department of Gastroenterology, Graduate School of MedicineJuntendo UniversityTokyoJapan
  4. 4.Department of Orthopaedic SurgeryJuntendo University School of MedicineTokyoJapan
  5. 5.Department of Respiratory Medicine, Graduate School of MedicineJuntendo UniversityTokyoJapan
  6. 6.Department of General Thoracic Surgery, Graduate School of MedicineJuntendo UniversityTokyoJapan
  7. 7.Department of Esophageal and Gastroenterological SurgeryJuntendo University School of MedicineTokyoJapan
  8. 8.Department of Gastroenterology and Minimally Invasive Surgery, Juntendo University HospitalJuntendo University School of MedicineTokyoJapan

Personalised recommendations